益方生物预计2025年归属净利润亏损2.92亿元

Core Viewpoint - Yifang Bio (688382) is expected to report a net profit attributable to shareholders of -292 million yuan for 2025, with projected operating revenue of 37.2452 million yuan, which is below 100 million yuan [1] Group 1: Financial Performance - The company anticipates a net loss of 292 million yuan for 2025 [1] - Projected operating revenue for 2025 is 37.2452 million yuan, which excludes unrelated business income and income without commercial substance [1] - The expected revenue is significantly lower than 100 million yuan [1] Group 2: Business Operations - The company has maintained high levels of R&D investment during the reporting period based on overall R&D progress for 2025 [1] - Current operating revenue primarily comes from licensing and collaboration, with variations in revenue composition from year to year [1] - The income from technology licensing and collaboration is not sufficient to cover costs and expenses, leading to continued losses in 2025 [1] Group 3: Competitive Position - Despite the anticipated losses, the company's core business and competitive strengths have not experienced significant adverse changes [1]